This is a multicenter, observational prospective cohort study in France and Germany.
Treatment centres with a focus on treating subjects with mCRC will be prospectively defined
for potential inclusion in the study. Eligible subjects will be enrolled and have
retrospective data collected from Baseline up to the point of enrolment. All subsequent
chemotherapy cycles and Vectibix® doses will be recorded prospectively. Each subject will
have data collected until approximately 30 days after the end of Vectibix® treatment, death,
withdrawal of consent, loss to follow-up or up to 12 months from the first dose of Vectibix®,
whichever occurs first.